Hemal Somaiya, Chief Strategy Officer, PharmaForceIQ

Articles by Hemal Somaiya, Chief Strategy Officer, PharmaForceIQ

Strategic advantage: Optichannel engagement drives ROI across the product lifecycle

ByHemal Somaiya, Chief Strategy Officer, PharmaForceIQ

August 5th 2025

Latest Updated Articles

Trending on PharmExec

Roundup: Novartis & Abogen Enter Licensing and Option Agreement, AstraZeneca and Daiichi Sankyo Enter Clinical Collaboration with Summit Therapeutics

Foghorn Therapeutics & Eli Lilly Halt Fhd-909 Development Following Phase I Data

How a Shift Towards Oral Medications Impacts GLP-1s

The Next Chapter in Metabolic Drug Development

Pharmaceutical Executive Daily: Foghorn Therapeutics & Eli Lilly Discontinue Development of FHD-909